As obesity is firmly linked to increased plasma RAS components levels, valsartan as AT-1 blocker has strong potential to gain weight loss, reduce glycemic level and enhance the expression of thermogenic genes. This evidence concerns the gene AGTR1 and obesity due to melanocortin 4 receptor deficiency.